Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Vidarsdottir, Solrun ; Roelfsema, Ferdinand ; Streefland, Trea ; Holst, Jens Juul ; Rehfeld, Jens F ; Pijl, Hanno. / Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. In: European Journal of Endocrinology. 2010 ; Vol. 162, No. 1. pp. 75-83.

Bibtex

@article{09b9e260aa464f6a9aa8131e8334982f,
title = "Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets",
abstract = "Treatment with olanzapine (atypical antipsychotic drug) is frequently associated with various metabolic anomalies, including obesity, dyslipidemia, and diabetes mellitus. Recent data suggest that olanzapine orally disintegrating tablets (ODT), which dissolve instantaneously in the mouth, might cause less weight gain than olanzapine standard oral tablets (OST).",
author = "Solrun Vidarsdottir and Ferdinand Roelfsema and Trea Streefland and Holst, {Jens Juul} and Rehfeld, {Jens F} and Hanno Pijl",
year = "2010",
month = "1",
day = "1",
doi = "10.1530/EJE-09-0433",
language = "English",
volume = "162",
pages = "75--83",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

AU - Vidarsdottir, Solrun

AU - Roelfsema, Ferdinand

AU - Streefland, Trea

AU - Holst, Jens Juul

AU - Rehfeld, Jens F

AU - Pijl, Hanno

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Treatment with olanzapine (atypical antipsychotic drug) is frequently associated with various metabolic anomalies, including obesity, dyslipidemia, and diabetes mellitus. Recent data suggest that olanzapine orally disintegrating tablets (ODT), which dissolve instantaneously in the mouth, might cause less weight gain than olanzapine standard oral tablets (OST).

AB - Treatment with olanzapine (atypical antipsychotic drug) is frequently associated with various metabolic anomalies, including obesity, dyslipidemia, and diabetes mellitus. Recent data suggest that olanzapine orally disintegrating tablets (ODT), which dissolve instantaneously in the mouth, might cause less weight gain than olanzapine standard oral tablets (OST).

U2 - 10.1530/EJE-09-0433

DO - 10.1530/EJE-09-0433

M3 - Journal article

VL - 162

SP - 75

EP - 83

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -

ID: 31047005